Table II.
Univariate Analysis for the Associations With Coronary Artery Calcification Progression
| <15%per Year | ≥15%per Year | P Value | |
|---|---|---|---|
| Number | 95 | 105 | |
| Age, y, mean ± SD | 48.0±2.8 | 47.7±2.8 | .51 |
| African American, % | 12 | 16.2 | .43 |
| Statin use, % | 47.5 | 52.5 | .56 |
| Aspirin use, % | 51.5 | 48.5 | .26 |
| Cardiac risk factors, % | |||
| Hypertension | 29.3 | 39 | .18 |
| Family history of CHD | 30.1 | 44.2 | .04 |
| Metabolic syndrome | 11.6 | 24.8 | .02 |
| Current tobacco use | 6.7 | 5.7 | .99 |
| Framingham CHD risk, % | 4.8±2.6 | 5.6±2.6 | .03 |
| Body mass index, kg/m2 | 28.4±3.0 | 28.1±2.9 | .47 |
| Waist girth, cm | 96.1±10.6 | 97.0±7.6 | .51 |
| Systolic blood pressure, mm Hg | 124.3±12.0 | 125.4±11.5 | .28 |
| Diastolic blood pressure, mm Hg | 78.5±8.6 | 78.8±7.4 | .47 |
| Total cholesterol, mg/dL | 208.8±39.8 | 217.5±38.0 | .05 |
| LDL cholesterol, mg/dL | 130.5±32.1 | 139.3±34.2 | .03 |
| HDL cholesterol, mg/dL | 50.4±9.7 | 47.8±11.9 | .12 |
| Triglycerides, mg/dL | 136.8±105.9 | 163.5±120.5 | .04 |
| Fasting glucose, mg/dL | 91.2±9.5 | 92.5±9.4 | .19 |
| C‐reactive protein, mg/dL | 1.5±1.2 | 1.8±1.5 | .09 |
| HOMA‐IR | 36.3±23.2 | 40.4±32.0 | .15 |
| Hemoglobin A1C, % | 5.3±0.51 | 5.4±0.49 | .36 |
Abbreviations: CHD, coronary heart disease; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model assessment of insulin resistance; LDL, low‐density lipoprotein.